CDSCO panel tells Abbott to present more data on Metronidazole Extended Release Tablet

Published On 2022-05-29 08:43 GMT   |   Update On 2022-05-29 08:43 GMT
Advertisement

New Delhi: Denying the pharmaceutical major Abbott Healthcare proposal to manufacture and market antibiotic Metronidazole Extended Release Tablet for the additional indication, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended the firm to present additional clinical and published data in support of the proposed additional indication.

This came during the SEC meeting for Dentistry held on 25th May 2022, where the proposal presented by pharma major Abbott Healthcare to manufacture and market antibiotic Metronidazole Extended Release Tablet 600mg for the additional indication was discussed.

Advertisement

Metronidazole is a medicine used to treat different types of bacterial and parasitic infections, including those that affect the skin, vagina, blood, heart, bone, stomach, liver, joints, nervous system, respiratory tract, and other areas of the body.

This medicine is also prescribed to treat sexually transmitted diseases (STDs). The extended-release form of metronidazole is used to treat bacterial vaginosis (an infection caused by too much harmful bacteria in the vagina) in women.

Metronidazole is in a class of drugs called nitroimidazole antimicrobials. It works by stopping the growth of bacteria.

This medicine will only help infections caused by bacteria and will not work for the common cold, flu, or other viral infections.

At the recent SEC meeting for Dentistry held on 25th May 2022, the expert panel reviewed the proposal presented by pharma major Abbott Healthcare to manufacture and market antibiotic Metronidazole Extended Release Tablet 600mg for the proposed additional indication.

After detailed deliberation, the committee recommended that the firm should present additional clinical and published data in support of the proposed additional indication before the committee for further consideration.

Also Read:Boehringer Ingelheim's empagliflozin gets CDSCO nod for heart failure with preserved ejection fraction

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News